Our results confirmed the synergistic therapeutic effects of this combination, which can continue to inhibit the AR signaling pathway during the CRPC stage, thereby delaying disease progression and improving the prognosis of patients with PCa. This evidence concerns the gene AR and posterior cortical atrophy.